PMID- 20445000
OWN - NLM
STAT- MEDLINE
DCOM- 20100525
LR  - 20220624
IS  - 1542-4863 (Electronic)
IS  - 0007-9235 (Print)
IS  - 0007-9235 (Linking)
VI  - 60
IP  - 3
DP  - 2010 May-Jun
TI  - Exciting new advances in neuro-oncology: the avenue to a cure for malignant 
      glioma.
PG  - 166-93
LID - 10.3322/caac.20069 [doi]
AB  - Malignant gliomas are the most common and deadly brain tumors. Nevertheless, 
      survival for patients with glioblastoma, the most aggressive glioma, although 
      individually variable, has improved from an average of 10 months to 14 months 
      after diagnosis in the last 5 years due to improvements in the standard of care. 
      Radiotherapy has been of key importance to the treatment of these lesions for 
      decades, and the ability to focus the beam and tailor it to the irregular 
      contours of brain tumors and minimize the dose to nearby critical structures with 
      intensity-modulated or image-guided techniques has improved greatly. 
      Temozolomide, an alkylating agent with simple oral administration and a favorable 
      toxicity profile, is used in conjunction with and after radiotherapy. Newer 
      surgical techniques, such as fluorescence-guided resection and neuroendoscopic 
      approaches, have become important in the management of malignant gliomas. 
      Furthermore, new discoveries are being made in basic and translational research, 
      which are likely to improve this situation further in the next 10 years. These 
      include agents that block 1 or more of the disordered tumor proliferation 
      signaling pathways, and that overcome resistance to already existing treatments. 
      Targeted therapies such as antiangiogenic therapy with antivascular endothelial 
      growth factor antibodies (bevacizumab) are finding their way into clinical 
      practice. Large-scale research efforts are ongoing to provide a comprehensive 
      understanding of all the genetic alterations and gene expression changes 
      underlying glioma formation. These have already refined the classification of 
      glioblastoma into 4 distinct molecular entities that may lead to different 
      treatment regimens. The role of cancer stem-like cells is another area of active 
      investigation. There is definite hope that by 2020, new cocktails of drugs will 
      be available to target the key molecular pathways involved in gliomas and reduce 
      their mortality and morbidity, a positive development for patients, their 
      families, and medical professionals alike.
FAU - Van Meir, Erwin G
AU  - Van Meir EG
AD  - Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, 
      USA. evanmei@emory.edu
FAU - Hadjipanayis, Costas G
AU  - Hadjipanayis CG
FAU - Norden, Andrew D
AU  - Norden AD
FAU - Shu, Hui-Kuo
AU  - Shu HK
FAU - Wen, Patrick Y
AU  - Wen PY
FAU - Olson, Jeffrey J
AU  - Olson JJ
LA  - eng
GR  - R01 CA086335/CA/NCI NIH HHS/United States
GR  - CA116804/CA/NCI NIH HHS/United States
GR  - R01 CA086335-09/CA/NCI NIH HHS/United States
GR  - K08 NS053454-01A1/NS/NINDS NIH HHS/United States
GR  - K08 NS053454-05/NS/NINDS NIH HHS/United States
GR  - CA86335/CA/NCI NIH HHS/United States
GR  - K08 NS053454/NS/NINDS NIH HHS/United States
GR  - K08 NS053454-04/NS/NINDS NIH HHS/United States
GR  - NS053454/NS/NINDS NIH HHS/United States
GR  - K08 NS053454-02/NS/NINDS NIH HHS/United States
GR  - K08 NS053454-03/NS/NINDS NIH HHS/United States
GR  - R01 CA116804-03S1/CA/NCI NIH HHS/United States
GR  - R01 CA116804/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - CA Cancer J Clin
JT  - CA: a cancer journal for clinicians
JID - 0370647
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis
MH  - Biomarkers, Tumor
MH  - Brain Neoplasms/genetics/pathology/*therapy
MH  - Epidermal Growth Factor/drug effects
MH  - Glioblastoma/genetics/pathology/*therapy
MH  - Humans
MH  - Molecular Biology
MH  - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
MH  - Signal Transduction
MH  - Treatment Failure
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
PMC - PMC2888474
MID - NIHMS202963
EDAT- 2010/05/07 06:00
MHDA- 2010/05/26 06:00
PMCR- 2010/08/01
CRDT- 2010/05/07 06:00
PHST- 2010/05/07 06:00 [entrez]
PHST- 2010/05/07 06:00 [pubmed]
PHST- 2010/05/26 06:00 [medline]
PHST- 2010/08/01 00:00 [pmc-release]
AID - 60/3/166 [pii]
AID - 10.3322/caac.20069 [doi]
PST - ppublish
SO  - CA Cancer J Clin. 2010 May-Jun;60(3):166-93. doi: 10.3322/caac.20069.